stockrow
Friday 6 November 2026
Export MDXG’s income statement to Excel — free account
MiMedx Group, Inc
MDXG Healthcare Biotechnology
MiMedx Group, Inc’s revenue for fiscal 2025 (year ended December 2025) was $418.6 million, up 20.0% from fiscal 2024.
- Revenue
- −45.2%
- EPS
- −154.1%
- Free cash flow
- −87.2%
- Total debt
- −6.80%
Quarter to September 2026, against a year earlier
3.31
0.03
+0.91%
Follow MDXG
Alert me
MiMedx Group, Inc (MDXG) P/E ratio
MiMedx Group, Inc has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 4,042× (March 2017) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 20.5× | (40.29%) |
| FY2024 | 34.4× | 74.62% |
| FY2023 | 19.7× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 21.3× | (99.42%) |
| FY2016 | 3,650× | 10,807.15% |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2026 | 0.0× | — |
| Jun 2026 | 96.3× | 411.71% |
| Mar 2026 | 18.8× | (8.31%) |
| Dec 2025 | 20.5× | (17.70%) |
| 43 more quarters | Free account |
Against its own ten years
Low 0.0×
High 4,042×
Ten-year median
11.3×
Current reading's percentile
43
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| CAPR Capricor Therapeutics, Inc. compare | n/m |
| INDP Indaptus Therapeutics, Inc. compare | n/m |
| CBIO Crescent Biopharma, Inc. compare | n/m |
| DMAC DiaMedica Therapeutics, Inc. compare | n/m |
| OVID Ovid Therapeutics compare | n/m |
| RGNX REGENXBIO Inc. compare | n/m |
| CTMX CytomX Therapeutics, Inc. compare | n/m |
| MDXG MiMedx Group, Inc | n/m |
| ETRA Electra Therapeutics Inc. compare | — |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)